Although their application in B-cell malignancies has not yet reached similarly satisfying results, preclinical experiments have highlighted the potential of targeting the BAFF/BAFF-R axis in CLL (41) and ALL (30). Here, TNFRSF13C is linked to B-cell chronic lymphocytic leukemia.